DPP-4 inhibitors for treating T2DM - hype or hope? an analysis based on the current literature
出版年份 2023 全文链接
标题
DPP-4 inhibitors for treating T2DM - hype or hope? an analysis based on the current literature
作者
关键词
-
出版物
Frontiers in Molecular Biosciences
Volume 10, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2023-05-23
DOI
10.3389/fmolb.2023.1130625
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Role and mechanism(s) of incretin-dependent therapies for treating diabetes mellitus
- (2022) Nasr E. Nasr et al. ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH
- A review upon medicinal perspective and designing rationale of DPP-4 inhibitors
- (2021) Shubham Kumar et al. BIOORGANIC & MEDICINAL CHEMISTRY
- The Impact of Glucose-Lowering Drugs on Sarcopenia in Type 2 Diabetes: Current Evidence and Underlying Mechanisms
- (2021) Elena Massimino et al. Cells
- Linagliptin, A Xanthine-Based Dipeptidyl Peptidase-4 Inhibitor, Ameliorates Experimental Autoimmune Myocarditis
- (2021) Yuka Shiheido-Watanabe et al. JACC-Basic to Translational Science
- GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials
- (2020) Matthew P. Gilbert et al. Frontiers in Endocrinology
- Drug Design of GLP-1 Receptor Agonists: Importance of In silico Methods
- (2020) Smriti Sharma et al. CURRENT PHARMACEUTICAL DESIGN
- The effects of dipeptidyl peptidase‐4 inhibitors on kidney outcomes
- (2020) Daniel V. O'Hara et al. DIABETES OBESITY & METABOLISM
- Ten years of experience with DPP-4 inhibitors for the treatment of type 2 diabetes mellitus
- (2019) Giorgio Sesti et al. ACTA DIABETOLOGICA
- Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes
- (2019) Carolyn F. Deacon Frontiers in Endocrinology
- The Role of DPP-4 Inhibitors in the Treatment Algorithm of Type 2 Diabetes Mellitus: When to Select, What to Expect
- (2019) Konstantinos Makrilakis International Journal of Environmental Research and Public Health
- DPP-4 Inhibitors as Potential Candidates for Antihypertensive Therapy: Improving Vascular Inflammation and Assisting the Action of Traditional Antihypertensive Drugs
- (2019) Jianqiang Zhang et al. Frontiers in Immunology
- Clinical Use of DPP-4 Inhibitors
- (2019) Baptist Gallwitz Frontiers in Endocrinology
- Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis
- (2019) Yue Fei et al. Cardiovascular Diabetology
- Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial
- (2019) David R Matthews et al. LANCET
- Surrogating and redirection of pyrazolo[1,5- a ]pyrimidin-7(4 H )-one core, a novel class of potent and selective DPP-4 inhibitors
- (2018) Xinxian Deng et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Do DPP-4 Inhibitors Cause Heart Failure Events by Promoting Adrenergically Mediated Cardiotoxicity?Novelty and Significance
- (2018) Milton Packer CIRCULATION RESEARCH
- Mechanisms and pathways of anti-inflammatory activity of DPP-4 inhibitors in cardiovascular and renal protection
- (2018) Katarina Tomovic et al. MEDICINAL RESEARCH REVIEWS
- Dipeptidyl peptidase-4 inhibitors, pancreatic cancer and acute pancreatitis: A meta-analysis with trial sequential analysis
- (2018) Lana C. Pinto et al. Scientific Reports
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019
- (2018) DIABETES CARE
- Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2018) Melanie J. Davies et al. DIABETES CARE
- Network meta-analysis of treatments for type 2 diabetes mellitus following failure with metformin plus sulfonylurea
- (2016) G. Lozano-Ortega et al. CURRENT MEDICAL RESEARCH AND OPINION
- Analyses of Results From Cardiovascular Safety Trials With DPP-4 Inhibitors: Cardiovascular Outcomes, Predefined Safety Outcomes, and Pooled Analysis and Meta-analysis
- (2016) Edoardo Mannucci et al. DIABETES CARE
- Evogliptin: a new dipeptidyl peptidase inhibitor for the treatment of type 2 diabetes
- (2016) Xueying Tan et al. EXPERT OPINION ON PHARMACOTHERAPY
- Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes
- (2016) Suetonia C. Palmer et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effect of Linagliptin on Vascular Function: A Randomized, Placebo-controlled Study
- (2016) Dimitrios Baltzis et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Sarcopenia in Elderly Diabetic Patients: Role of Dipeptidyl Peptidase 4 Inhibitors
- (2016) Maria Rosaria Rizzo et al. Journal of the American Medical Directors Association
- Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes Mellitus
- (2016) Sung-Ho Kim et al. Diabetes & Metabolism Journal
- Trelagliptin (SYR-472, Zafatek), Novel Once-Weekly Treatment for Type 2 Diabetes, Inhibits Dipeptidyl Peptidase-4 (DPP-4) via a Non-Covalent Mechanism
- (2016) Charles E. Grimshaw et al. PLoS One
- Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis
- (2016) Heidi Storgaard et al. PLoS One
- Saxagliptin: A Review in Type 2 Diabetes
- (2015) Sohita Dhillon DRUGS
- Omarigliptin: First Global Approval
- (2015) Celeste B. Burness DRUGS
- DPP4 in diabetes
- (2015) Diana Röhrborn Frontiers in Immunology
- Anagliptin in the treatment of type 2 diabetes: safety, efficacy, and patient acceptability
- (2015) Hiroyuki Ito et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials
- (2014) Nayyar Iqbal et al. Cardiovascular Diabetology
- Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
- (2014) Silvio E. Inzucchi et al. DIABETES CARE
- Clinical utility of dipeptidyl peptidase-4 inhibitors: a descriptive summary of current efficacy trials
- (2014) George Grunberger EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- DPP-4 inhibitors: pharmacological differences and their clinical implications
- (2014) Antonio Ceriello et al. Expert Opinion On Drug Safety
- DPP-4 inhibitors: focus on safety
- (2014) Sri Harsha Tella et al. Expert Opinion On Drug Safety
- Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation
- (2014) N Waugh et al. HEALTH TECHNOLOGY ASSESSMENT
- Pancreatic Safety of Incretin-Based Drugs — FDA and EMA Assessment
- (2014) Amy G. Egan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sitagliptin Use in Patients With Diabetes and Heart Failure
- (2014) Daniala L. Weir et al. JACC-Heart Failure
- GLP-1 receptor agonists: a review of head-to-head clinical studies
- (2014) Jennifer M. Trujillo et al. Therapeutic Advances in Endocrinology and Metabolism
- Effects of Sitagliptin and Metformin Treatment on Incretin Hormone and Insulin Secretory Responses to Oral and "Isoglycemic" Intravenous Glucose
- (2013) I. Vardarli et al. DIABETES
- The dipeptidylpeptidase-IV inhibitors sitagliptin, vildagliptin and saxagliptin do not impair innate and adaptive immune responses
- (2013) D. Anz et al. DIABETES OBESITY & METABOLISM
- Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials
- (2013) M. Monami et al. DIABETES OBESITY & METABOLISM
- Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis
- (2013) J. A. Hirst et al. DIABETOLOGIA
- Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control
- (2013) Helena Rodbard et al. Endocrine Practice
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects on Lipid Profile of Dipeptidyl Peptidase 4 Inhibitors, Pioglitazone, Acarbose, and Sulfonylureas: Meta-analysis of Placebo-Controlled Trials
- (2012) Matteo Monami et al. ADVANCES IN THERAPY
- Pharmacology, Efficacy, and Safety of Linagliptin for the Treatment of Type 2 Diabetes Mellitus
- (2012) Joshua J Neumiller ANNALS OF PHARMACOTHERAPY
- Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): A highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
- (2012) Tomohiro Yoshida et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme
- (2012) Odd Johansen et al. Cardiovascular Diabetology
- Clinical Pharmacokinetics and Pharmacodynamics of Vildagliptin
- (2012) Yan-Ling He CLINICAL PHARMACOKINETICS
- Cardiovascular effects of the DPP-4 inhibitors
- (2012) Tessey Jose et al. Diabetes & Vascular Disease Research
- Pharmacokinetic evaluation of atorvastatin and sitagliptin in combination for the treatment of type 2 diabetes
- (2012) André J Scheen Expert Opinion on Drug Metabolism & Toxicology
- Alogliptin benzoate for the treatment of type 2 diabetes
- (2012) Marc Rendell et al. EXPERT OPINION ON PHARMACOTHERAPY
- Vildagliptin Reduces Glucagon during Hyperglycemia and Sustains Glucagon Counterregulation during Hypoglycemia in Type 1 Diabetes
- (2012) Johan Farngren et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients
- (2012) Noriko Satoh-Asahara et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Long-Term Dipeptidyl-Peptidase 4 Inhibition Reduces Atherosclerosis and Inflammation via Effects on Monocyte Recruitment and Chemotaxis
- (2011) Zubair Shah et al. CIRCULATION
- Effect of Multiple Oral Doses of Linagliptin on the Steady-State Pharmacokinetics of a Combination Oral Contraceptive in Healthy Female Adults
- (2011) Christian Friedrich et al. CLINICAL DRUG INVESTIGATION
- Diet-Induced Adipose Tissue Inflammation and Liver Steatosis Are Prevented by DPP-4 Inhibition in Diabetic Mice
- (2011) J. Shirakawa et al. DIABETES
- DPP-4 inhibitors in the management of type 2 diabetes: A critical review of head-to-head trials
- (2011) A.J. Scheen DIABETES & METABOLISM
- Efficacy of Insulin Analogs in Achieving the Hemoglobin A1c Target of
- (2011) D. Giugliano et al. DIABETES CARE
- DPP-4 Inhibitors: Impact on glycemic control and cardiovascular risk factors
- (2011) D. Dicker DIABETES CARE
- Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study
- (2011) E. Bosi et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of linagliptin in persons with Type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study1
- (2011) D. R. Owens et al. DIABETIC MEDICINE
- A review of gliptins in 2011
- (2011) André J Scheen EXPERT OPINION ON PHARMACOTHERAPY
- Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product–receptor axis
- (2011) Takanori Matsui et al. PHARMACOLOGICAL RESEARCH
- Efficacy and Safety of Saxagliptin Combination Therapy in US Patients with Type 2 Diabetes
- (2011) Chetan Karyekar et al. POSTGRADUATE MEDICINE
- Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways
- (2011) Zubair Shah et al. VASCULAR PHARMACOLOGY
- Cardiovascular effects of DPP-4 inhibition: Beyond GLP-1
- (2011) Gian Paolo Fadini et al. VASCULAR PHARMACOLOGY
- DPP-4 Inhibition by Sitagliptin Improves the Myocardial Response to Dobutamine Stress and Mitigates Stunning in a Pilot Study of Patients With Coronary Artery Disease
- (2010) Philip A. Read et al. Circulation-Cardiovascular Imaging
- Dipeptidylpeptitase-4 Inhibitors (Gliptins)
- (2010) André J. Scheen CLINICAL PHARMACOKINETICS
- Pharmacokinetics of dipeptidylpeptidase-4 inhibitors
- (2010) A. J. Scheen DIABETES OBESITY & METABOLISM
- An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials
- (2010) M. Ligueros-Saylan et al. DIABETES OBESITY & METABOLISM
- Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review
- (2010) C. F. Deacon DIABETES OBESITY & METABOLISM
- DPP-4 inhibitors: What may be the clinical differentiators?
- (2010) John Gerich DIABETES RESEARCH AND CLINICAL PRACTICE
- Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes
- (2010) T. Forst et al. DIABETIC MEDICINE
- Assessment of the Pharmacokinetic Interaction between the Novel DPP-4 Inhibitor Linagliptin and a Sulfonylurea, Glyburide, in Healthy Subjects
- (2010) Ulrike Graefe-Mody et al. Drug Metabolism and Pharmacokinetics
- Sitagliptin
- (2010) Sohita Dhillon DRUGS
- Molecular mechanisms underlying nutrient-stimulated incretin secretion
- (2010) Helen E. Parker et al. EXPERT REVIEWS IN MOLECULAR MEDICINE
- Effects of One Year Treatment of Vildagliptin Added to Pioglitazone or Glimepiride in Poorly Controlled Type 2 Diabetic Patients
- (2010) G. Derosa et al. HORMONE AND METABOLIC RESEARCH
- Interactive Hemodynamic Effects of Dipeptidyl Peptidase-IV Inhibition and Angiotensin-Converting Enzyme Inhibition in Humans
- (2010) Annis Marney et al. HYPERTENSION
- Nature of action of sitagliptin, the dipeptidyl peptidase-IV inhibitor in diabetic animals
- (2010) JosephA Davis et al. INDIAN JOURNAL OF PHARMACOLOGY
- Effect of Noninsulin Antidiabetic Drugs Added to Metformin Therapy on Glycemic Control, Weight Gain, and Hypoglycemia in Type 2 Diabetes
- (2010) Olivia J. Phung JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Endogenous GLP-1 Regulates Postprandial Glycemia in Humans: Relative Contributions of Insulin, Glucagon, and Gastric Emptying
- (2010) Mathias Nicolaus et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Addition of incretin therapy to metformin in type 2 diabetes
- (2010) André J Scheen et al. LANCET
- A Meta-Analysis of Placebo-Controlled Clinical Trials Assessing the Efficacy and Safety of Incretin-Based Medications in Patients with Type 2 Diabetes
- (2010) Walid K.H. Fakhoury et al. PHARMACOLOGY
- Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes Mellitus
- (2010) Joshua J Neumiller et al. PHARMACOTHERAPY
- A Systematic Assessment of Cardiovascular Outcomes in the Saxagliptin Drug Development Program for Type 2 Diabetes
- (2010) Robert Frederich et al. POSTGRADUATE MEDICINE
- Saxagliptin for type 2 diabetes
- (2010) Chacra Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- DPP4 inhibitors: from sitagliptin monotherapy to the new alogliptin-pioglitazone combination therapy
- (2009) Georgia Argyrakopoulou et al. ADVANCES IN THERAPY
- Drug evaluation: Vildagliptin-metformin single-tablet combination
- (2009) Abd A. Tahrani et al. ADVANCES IN THERAPY
- Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus
- (2009) Abd A. Tahrani et al. ADVANCES IN THERAPY
- Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes
- (2009) Shrikanth H. Havale et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Tissue distribution of the novel DPP-4 inhibitor BI 1356 is dominated by saturable binding to its target in rats
- (2009) Holger Fuchs et al. BIOPHARMACEUTICS & DRUG DISPOSITION
- Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers
- (2009) Kyoung Soo Lim et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes
- (2009) J. Rosenstock et al. CURRENT MEDICAL RESEARCH AND OPINION
- The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone
- (2009) R. A. DeFronzo et al. DIABETES CARE
- Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1cwithout causing weight gain or increased hypoglycaemia
- (2009) J. Rosenstock et al. DIABETES OBESITY & METABOLISM
- Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial
- (2009) M. Jadzinsky et al. DIABETES OBESITY & METABOLISM
- Investigation of the effect of oral metformin on dipeptidylpeptidase-4 (DPP-4) activity in Type 2 diabetes
- (2009) J. Cuthbertson et al. DIABETIC MEDICINE
- Long-term glycaemic control with metformin-sulphonylurea-pioglitazone triple therapy in PROactive (PROactive 17)
- (2009) A. J. Scheen et al. DIABETIC MEDICINE
- Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes
- (2009) Carolyn F Deacon et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Vildagliptin in clinical practice: a review of literature
- (2009) Moulinath Banerjee et al. EXPERT OPINION ON PHARMACOTHERAPY
- Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial
- (2009) A. R. Chacra et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Multiple Doses of Sitagliptin, a Selective DPP-4 Inhibitor, Do Not Meaningfully Alter Pharmacokinetics and Pharmacodynamics of Warfarin
- (2009) D. Hamish Wright et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Coadministration of Pioglitazone or Glyburide and Alogliptin: Pharmacokinetic Drug Interaction Assessment in Healthy Participants
- (2009) Aziz Karim et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations
- (2009) Raffaele Marfella et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors
- (2009) Joshua J. Neumiller JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION
- Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients
- (2009) Giuseppe Derosa et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- DPP-4 Inhibitors in Clinical Practice
- (2009) Anna I. Palalau et al. POSTGRADUATE MEDICINE
- Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?
- (2009) Roger Yazbeck et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study
- (2008) Ralph A. DeFronzo et al. CURRENT MEDICAL RESEARCH AND OPINION
- Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes
- (2008) J.-F. Gautier et al. DIABETES & METABOLISM
- Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Alogliptin in Patients With Type 2 Diabetes and Inadequate Glycemic Control: A randomized, double-blind, placebo-controlled study
- (2008) R. A. DeFronzo et al. DIABETES CARE
- Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy
- (2008) B. Schwarz et al. DIABETES OBESITY & METABOLISM
- Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia*
- (2008) W. A. Scherbaum et al. DIABETES OBESITY & METABOLISM
- New Drugs for Type 2 Diabetes Mellitus
- (2008) Andrew J Krentz et al. DRUGS
- Janumet™: a combination product suitable for use in patients with Type 2 diabetes
- (2008) Jonathan Kent Reynolds et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Efficacy and Safety of Vildagliptin Monotherapy during 2-Year Treatment of Drug-naïve Patients with Type 2 Diabetes: Comparison with Metformin
- (2008) B. Göke et al. HORMONE AND METABOLIC RESEARCH
- Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study
- (2008) M. A. Nauck et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Dipeptidyl-Peptidase-IV Inhibition Augments Postprandial Lipid Mobilization and Oxidation in Type 2 Diabetic Patients
- (2008) Michael Boschmann et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of BI 1356, an Inhibitor of Dipeptidyl Peptidase 4, in Healthy Male Volunteers
- (2008) S. Hüttner et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Effect of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Blood Pressure in Nondiabetic Patients With Mild to Moderate Hypertension
- (2008) Goutam C. Mistry et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Pharmacokinetics and Pharmacodynamics of Vildagliptin in Healthy Chinese Volunteers
- (2008) Pei Hu et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Involvement of DPP-IV catalytic residues in enzyme-saxagliptin complex formation
- (2008) William J. Metzler et al. PROTEIN SCIENCE
- Characterization of the Influence of Vildagliptin on Model-Assessed β-Cell Function in Patients with Type 2 Diabetes and Mild Hyperglycemia
- (2007) Andrea Mari et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started